TP53 and non-small cell lung carcinoma: Additionally, a study in the Brazilian population concluded that concurrent variant of TP53 had a potentially negative predictive effect associated with platinum-based chemotherapy and erlotinib in early-stage EGFR-mutated NSCLC [33].